Sagimet Biosciences Future Growth
Future criteria checks 2/6
Sagimet Biosciences's earnings are forecast to decline at 33.5% per annum while its annual revenue is expected to grow at 85.5% per year. EPS is expected to decline by 24.8% per annum. Return on equity is forecast to be -35.2% in 3 years.
Key information
-33.5%
Earnings growth rate
-24.8%
EPS growth rate
| Biotechs earnings growth | 28.3% |
| Revenue growth rate | 85.5% |
| Future return on equity | -35.2% |
| Analyst coverage | Good |
| Last updated | 15 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Sagimet: More Than Just A MASH Drug Development Biotech
Nov 14Sagimet Soars: FDA Breakthrough Therapy Designation And Lancet Review Validate Denifanstat
Oct 18Sagimet Biosciences' Denifanstat Remains A Strong Buy Despite Eli Lilly's Tirzepatide
Jul 31Companies Like Sagimet Biosciences (NASDAQ:SGMT) Are In A Position To Invest In Growth
May 31
Sagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunity
Apr 26Sagimet: Additional Upside Possible After Latest NASH Data Release
Jan 24Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0 | -190 | N/A | N/A | 5 |
| 12/31/2025 | 2 | -115 | N/A | N/A | 6 |
| 12/31/2024 | N/A | -51 | N/A | N/A | 5 |
| 9/30/2024 | N/A | -38 | -38 | -38 | N/A |
| 6/30/2024 | 2 | -29 | -23 | -23 | N/A |
| 3/31/2024 | 2 | -28 | -23 | -23 | N/A |
| 12/31/2023 | 2 | -28 | -24 | -24 | N/A |
| 9/30/2023 | 2 | -27 | -24 | -24 | N/A |
| 6/30/2023 | N/A | -28 | -26 | -26 | N/A |
| 3/31/2023 | N/A | -28 | -27 | -27 | N/A |
| 12/31/2022 | N/A | -30 | -24 | -24 | N/A |
| 12/31/2021 | N/A | -24 | -22 | -22 | N/A |
| 12/31/2020 | N/A | -11 | -10 | -10 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: SGMT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: SGMT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: SGMT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: SGMT's revenue (85.5% per year) is forecast to grow faster than the US market (9% per year).
High Growth Revenue: SGMT's revenue (85.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: SGMT is forecast to be unprofitable in 3 years.